Meloxicam (Mobic®) Receives FDA Approval

Earlier this month, meloxicam (Mobic) received approval from the Food and Drug Administration (FDA) for use in osteoarthritis (OA). It is indicated for relief of the signs and symptoms of OA. Mobic is contraindicated in patients with known hypersensitivity to meloxicam and should not be given to patients who have experienced any allergic type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).